Ligand Pharmaceuticals Incorporated (LGND) Q4 2011 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.64%

Ligand Pharmaceuticals reported a significant EPS beat, which indicates strong profitability relative to expectations. However, the stock fell slightly by 0.64%, suggesting that investors may have been looking for additional revenue details or future guidance. The lack of guidance could lead to uncertainty among investors as they assess the company's future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.24	N/A	+1100.00%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management expressed satisfaction with the EPS results but did not provide specific guidance for future quarters. They focused on the importance of strategic initiatives.

Management highlighted the strong EPS performance despite lacking revenue guidance.

They emphasized ongoing efforts to enhance product pipeline and partnerships.

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.64%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.64%

Key numbers

Management commentary